 SAN DIEGO--BUSINESS WIRE--Quidel Corporation NASDAQ: QDEL Quidel, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today preliminary results for the third quarter of 2021. Quidel expects total revenues in the third quarter of 2021 to be in the range of 505 million to 510 million, an increase of between 6 and 7 from 476.1 million in the third quarter of 2020. In the third quarter of 2021, Quidel shipped over 